Merck & Co. Files 8-K on Financials

Ticker: MRK · Form: 8-K · Filed: 2025-04-24T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, results-of-operations

Related Tickers: MRK

TL;DR

Merck filed an 8-K on 4/24/25 detailing financial results. Check it for performance updates.

AI Summary

Merck & Co., Inc. filed an 8-K on April 24, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's financial performance. Specific details regarding the financial results or any significant events are not elaborated upon in the provided text, but the filing indicates a focus on financial reporting.

Why It Matters

This filing provides an official update on Merck's financial health and operational results, which is crucial for investors and stakeholders to assess the company's performance and future outlook.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing with no immediate indication of significant negative events.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K filing?

The provided text indicates the filing is related to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not specify the actual financial figures or performance metrics.

When was this 8-K filing submitted to the SEC?

The filing was submitted on April 24, 2025.

What is the Central Index Key (CIK) for Merck & Co., Inc.?

The CIK for Merck & Co., Inc. is 0000310158.

What is the primary purpose of this 8-K filing?

The primary purpose is to report on Merck & Co., Inc.'s results of operations and financial condition, along with associated financial statements and exhibits.

Does the filing mention any specific acquisitions or divestitures?

The provided text of the filing does not mention any specific acquisitions or divestitures; it focuses on general financial reporting.

From the Filing

0001104659-25-038301.txt : 20250424 0001104659-25-038301.hdr.sgml : 20250424 20250424064516 ACCESSION NUMBER: 0001104659-25-038301 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250424 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250424 DATE AS OF CHANGE: 20250424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 25863502 BUSINESS ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 8-K 1 tm2512885d1_8k.htm FORM 8-K false 0000310158 0000310158 2025-04-24 2025-04-24 0000310158 us-gaap:CommonStockMember 2025-04-24 2025-04-24 0000310158 mrk:Sec1.875NotesDue2026Member 2025-04-24 2025-04-24 0000310158 mrk:Sec3.250NotesDue2032Member 2025-04-24 2025-04-24 0000310158 mrk:Sec2.500NotesDue2034Member 2025-04-24 2025-04-24 0000310158 mrk:Sec1.375NotesDue2036Member 2025-04-24 2025-04-24 0000310158 mrk:Sec3.500NotesDue2037Member 2025-04-24 2025-04-24 0000310158 mrk:Sec3.700NotesDue2044Member 2025-04-24 2025-04-24 0000310158 mrk:Sec3.750NotesDue2054Member 2025-04-24 2025-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) April 24, 2025 ( April 24, 2025 )   Merck & Co., Inc. (Exact name of registrant as specified in its charter)   New Jersey (State or other jurisdiction of incorporation)   1-6571 (Commission File Number)   22-1918501 (I.R.S. Employer Identification No.)   126 East Lincoln Avenue , Rahway , NJ (Address of principal executive offices)   07065 (Zip Code)   Registrant’s telephone number, including area code ( 732 ) 594-4000   Not Applicable (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered           Common Stock ($0.50 par value)   MRK   New York Stock Exchange 1.875% Notes due 2026   MRK/26   New York Stock Exchange 3.250% Notes due 2032   MRK/32   New York Stock Exchange 2.500% Notes due 2034   MRK/34   New York Stock Exchange 1.375% Notes due 2036   MRK 36A   New York Stock Exchange 3.500% Notes due 2037   MRK/37   New York Stock Exchange 3.700% Notes due 2044   MRK/44   New York Stock Exchange 3.750% Notes due 2054   MRK/54   New York Stock Exchange   I

View on Read The Filing